144 related articles for article (PubMed ID: 12771302)
41. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients.
Levine BS; Song M
J Am Soc Nephrol; 1996 Mar; 7(3):488-96. PubMed ID: 8704116
[TBL] [Abstract][Full Text] [Related]
42. 1.25(OH)2 cholecalciferol pulse therapy and the effects of different dialysis membranes on serum PTH levels of haemodialysis patients.
Boran M; Doruk E; Gönenç F; Cetin S
Int Urol Nephrol; 1997; 29(2):251-8. PubMed ID: 9241557
[TBL] [Abstract][Full Text] [Related]
43. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient.
Rodriguez M; Caravaca F; Fernandez E; Borrego MJ; Lorenzo V; Cubero J; Martin-Malo A; Betriu A; Jimenez A; Torres A; Felsenfeld AJ
Kidney Int; 1999 Jul; 56(1):306-17. PubMed ID: 10411707
[TBL] [Abstract][Full Text] [Related]
44. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism.
Dressler R; Laut J; Lynn RI; Ginsberg N
Clin Nephrol; 1995 May; 43(5):324-31. PubMed ID: 7634548
[TBL] [Abstract][Full Text] [Related]
45. [PEIT is the part of strategy for severe hyperparathyroidism in patients requiring hemodialysis].
Uemura K; Kakuta T
Clin Calcium; 2004 Sep; 14(9):88-92. PubMed ID: 15577118
[TBL] [Abstract][Full Text] [Related]
46. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
Bacchini G; Fabrizi F; Pontoriero G; Marcelli D; Di Filippo S; Locatelli F
Nephron; 1997; 77(3):267-72. PubMed ID: 9375818
[TBL] [Abstract][Full Text] [Related]
47. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
[TBL] [Abstract][Full Text] [Related]
48. Dynamic follow-up of the intact parathormone levels in hemodialysis patients treated with Rocaltrol and calcium.
Dimitrakov D; Koumtchev E; Dimitrova R; Stavrev P
Folia Med (Plovdiv); 1998; 40(4):48-53. PubMed ID: 10371800
[TBL] [Abstract][Full Text] [Related]
49. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A
Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173
[TBL] [Abstract][Full Text] [Related]
50. Parathyroid interventions for secondary hyperparathyroidism in hemodialyzed patients.
Onoda N; Kashiwagi T; Nakamura T; Niitsu Y; Omata M; Kurihara S
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S11-5. PubMed ID: 16109135
[TBL] [Abstract][Full Text] [Related]
51. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
Ardissino G; Schmitt CP; Bianchi ML; Daccò V; Claris-Appiani A; Mehls O
Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
[TBL] [Abstract][Full Text] [Related]
52. Intraperitoneal calcitriol in infants on peritoneal dialysis.
Cano FJ; Azocar MA; Guerrero JL; Delucchi MA; Lillo AM; Emilfork M; Rodríguez EE
Perit Dial Int; 2007; 27(6):681-6. PubMed ID: 17984431
[TBL] [Abstract][Full Text] [Related]
53. Effects of percutaneous ethanol injection therapy on subsequent parathyroidectomy.
Chen HH; Hsu MT; Wu CJ; Chen YW; Yang TL
Am J Surg; 2008 Aug; 196(2):155-9. PubMed ID: 18513687
[TBL] [Abstract][Full Text] [Related]
54. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
55. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
[TBL] [Abstract][Full Text] [Related]
56. Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients.
Huraib S; Abu-Aisha H; Abed J; Al Wakeel J; Al Desouki M; Memon N
Am J Nephrol; 1997; 17(2):118-23. PubMed ID: 9096441
[TBL] [Abstract][Full Text] [Related]
57. Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients.
Shiizaki K; Negi S; Mizobuchi M; Hatamura I; Narukawa N; Sakaguchi T; Kitabata Y; Sumikado S; Akizawa T
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii42-6. PubMed ID: 12771299
[TBL] [Abstract][Full Text] [Related]
58. [The clinical evaluation of maxacalcitol on therapy for secondary hyperparathyroidism of chronic hemodialysis patients].
Kasai K; Abe R; Wakabayashi M; Nakamura K; Sawatani S; Wakabayashi T
Nihon Jinzo Gakkai Shi; 2002; 44(5):464-70. PubMed ID: 12216479
[TBL] [Abstract][Full Text] [Related]
59. Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients.
Doi S; Yorioka N; Usui K; Shigemoto K; Harada S
Intern Med; 2003 Oct; 42(10):955-9. PubMed ID: 14606707
[TBL] [Abstract][Full Text] [Related]
60. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients.
Kakuta T; Fukagawa M; Fujisaki T; Hida M; Suzuki H; Sakai H; Kurokawa K; Saito A
Am J Kidney Dis; 1999 Jun; 33(6):1091-9. PubMed ID: 10352197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
